<DOC>
	<DOCNO>NCT00255567</DOCNO>
	<brief_summary>The purpose study assess efficacy safety SSG 30 day alone , PM 21 day alone SSG PM combination course 17 day treatment patient VL .</brief_summary>
	<brief_title>Efficacy/Safety Sodium Stibogluconate ( SSG ) Versus Paromomycin ( PM ) SSG/PM Combination Treat V Leishmaniasis</brief_title>
	<detailed_description>Currently three country , Sudan , Kenya Ethiopia many patient present remote area need treat relative resource poor setting . It reason standardise treatment proven efficacy much need . A short course treatment advantageous patient also reduce overall case load clinic thus reduce risk disease outbreak already immuno-compromised kala-azar patient . Paromomycin , either alone combination SSG would decrease treatment duration substantially . An additional add value combination therapy likely reduce chance development parasite resistance individual drug . Leishmaniasis expert three country agreement potential benefit combination treatment SSG PM efficacy evaluate view introduce protocol proven efficacious safe . There ample circumstantial evidence use combination therapy efficacy tolerability standardize protocol . This confirm randomise control study 6 month follow .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Paromomycin</mesh_term>
	<mesh_term>Antimony Sodium Gluconate</mesh_term>
	<criteria>1 . Patients write informed consent sign patient ( age 18 year ) parent ( ) legal guardian patient 18 year age . 2 . Patients age 4 60 year ( inclusive ) able comply protocol . It justify include child represent 50 % VL case . 3 . Patients clinical sign symptom VL diagnosis confirm visualization parasite tissue sample ( spleen , lymph node bone marrow ) microscopy . 1 . Patients receive antileishmanial drug last 6 month . 2 . Patients negative splenic / lymph node / bone marrow smear . 3 . Patients clinical contraindication splenic/lymph node/ bone marrow aspirate . 4 . Patients severe protein caloric malnutrition ( Kwashiokor marasmus ) 5 . Patients previous hypersensitivity reaction SSG aminoglycosides . 6 . Patients suffer concomitant severe infection TB serious underlie disease ( cardiac , renal , hepatic ) would preclude evaluation patient response study medication . 7 . Patients suffer condition associate splenomegaly schistosomiasis . 8 . Patients previous history cardiac arrhythmia abnormal ECG 9 . Patients pregnant lactate . 10 . Patients haemoglobin &lt; 5gm/dl . 11 . Patients WBC &lt; 1 x 10³/mm³ . 12 . Patients platelets &lt; 40,000/mm³ . 13 . Patients liver function test three time normal range 14 . Patients serum creatinine outside normal range age gender 15 . Patients preexist clinical hearing loss .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Visceral Leishmaniasis</keyword>
	<keyword>Combination</keyword>
</DOC>